US Patent 10221160 Metalloenzyme inhibitor compounds
Patent 10221160 was granted and assigned to Mycovia Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+195 characters)
Article
Patent abstract
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Robert J. Schotzinger0
Stephen W. Rafferty0
William J. Hoekstra0
Edits on 3 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 2 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 16 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 31 Jan, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10221160 Metalloenzyme inhibitor compounds
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10221160
Date of patent
March 5, 2019
Patent application number
14373314
Date Filed
January 18, 2013
Patent citations
Patent primary examiner
Find more entities like US Patent 10221160 Metalloenzyme inhibitor compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
